Symetis' second-gen TAVI device shows positive trial results

04/5/2013 | MassDevice.com (Boston)

Symetis' Acurate TA device, a second-generation transcatheter aortic valve implant already approved in Europe, showed a 98% rate of procedural success and minimal valve leakage in a 250-patient clinical study. The device also showed a 6.8% all-cause mortality rate at 30 days, which the company said was one of the lowest rates reported for TAVI devices.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT